专注于创新生物打印技术和生物墨水的开发和商业化的CELLINK今天宣布，该公司将与阿斯特捷利康药厂（AstraZeneca）合作，提供先进的3D生物打印肝脏类器官，用于心血管，肾脏和代谢性疾病的药物研发。

3D生物打印已成为一种有用的技术，可以概括天然组织的微环境，从而可以将多个细胞精确地打印到预定位置。

CELLINK在阿斯利康位于瑞典哥德堡的BioVentureHub设有研发实验室。这项新的合作将利用CELLINK的创新且正在申请专利的生物墨水，Extra Cellular Matrix和层粘连蛋白为基础的生物墨水，使人体细胞能够像在人体中那样生长和发挥作用。

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

In tissue engineering, the need for assembly of three-dimensional (3D) tissues is important. 3D-bioprinting has emerged as a useful technology to recapitulate the microenvironment of native tissue, allowing for precise printing of multiple cells into a pre-defined position.

CELLINK has an R&D lab in AstraZeneca’s BioVentureHub in Gothenburg, Sweden. The new collaboration will leverage CELLINK’s innovative and patent-pending bioink, Extra Cellular Matrix and Laminin based bioinks, which enables human cells to grow and function as they would in the human body.